-

We Row For William: 157 Miles, One Nonstop Journey of Hope

Father and Crew to Row 157 Miles Continuously to Fund Lifesaving Gene Therapy for His Son

original

MEDFORD, Ore.--(BUSINESS WIRE)--On April 25, Joe Jackson and a dedicated crew of men including Jeremy Leever and Shaun Olson will embark on an extraordinary nonstop, overnight rowing journey covering 157 miles of the Rogue River to raise awareness and critical funds for his son, William Jackson, who is battling Duchenne muscular dystrophy (DMD).

What typically takes 10 days, Joe and his crew will complete in a single, grueling push, symbolizing the urgency of finding a cure for this relentless disease. The Rogue River is one of the nation’s most famous whitewater.

Duchenne muscular dystrophy is a progressive, life-limiting genetic disorder that causes muscle degeneration and weakness. To save William and other boys like him, the Jackson family is urgently working to raise $2.2 million to complete development of a CRISPR-based gene therapy. This drug development effort is spearheaded by Cure Rare Disease, a nonprofit biotech pioneering genetic treatment for ultra-rare diseases.

Their first crucial milestone is $800,000 by May 1, a goal they can reach if all 157 miles of this journey are sponsored.

“This is a race against time,” said Joe Jackson. “Rowing 157 miles straight is nothing compared to what William faces every day. We’re doing this to give him and other boys like him a real chance at life.”

How to Get Involved: WeRowForWilliam.org

  • Sponsor a Mile: Each mile sponsored brings William closer to his first fundraising goal.
  • Donate: Every contribution supports the development of a life-saving gene therapy.
  • Spread the Word: Share William’s story and help make an impact.

Every dollar raised will directly fund the development of a first-of-its-kind CRISPR-based gene therapy for William and others fighting Duchenne.

To sponsor a mile, donate, or learn more, visit WeRowForWilliam.org/raiselysite.com or contact Brittany Stineman at Brittany@curerd.org.

About Cure Rare Disease

The mission of Cure Rare Disease is to develop and fund life-saving genetic therapies for ultra-rare diseases, transforming the lives of patients previously deemed untreatable. By fostering strategic collaborations among top researchers, clinicians, policy experts, and donors, Cure Rare Disease brings hope and advances solutions for those awaiting a cure.

Contacts

Media Inquiries:
Brittany Stineman
Brittany@curerd.org
773-751-9010

Industry:

CURE RARE DISEASE

Details
Headquarters: Boston, USA
CEO: Richard Horgan
Employees: 5
Organization: NON
Release Versions
English

Contacts

Media Inquiries:
Brittany Stineman
Brittany@curerd.org
773-751-9010

Social Media Profiles
Cure Rare Disease Facebook Account
Cure Rare Disease Instagram Account
Cure Rare Disease LinkedIn Account
Cure Rare Disease Twitter Account
Cure Rare Disease YouTube Account
More News From CURE RARE DISEASE

Cure Rare Disease Welcomes New Scientific and Strategic Leaders to Advance Therapies for Ultra-Rare Conditions

WOODBRIDGE, Conn.--(BUSINESS WIRE)--Cure Rare Disease (CRD), a clinical-stage nonprofit biotechnology organization developing genetic therapies for ultra-rare conditions, is proud to announce the appointment of Keith Sutton, PhD, as Chief Science Officer and the addition of Michelle Werner to its Board of Directors. These strategic additions bring deep scientific expertise and seasoned biopharmaceutical leadership to CRD as the organization continues to advance therapeutic development for rare...

Cure Rare Disease Receives Orphan Drug Designation from FDA for Investigational Therapy Targeting Spinocerebellar Ataxia Type 3 (SCA3)

WOODBRIDGE, Conn.--(BUSINESS WIRE)--Cure Rare Disease (CRD), a clinical-stage nonprofit biotechnology company developing genetic medicines for ultra-rare and rare conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its investigational anti-sense Oligonucleotide therapeutic for the treatment of Spinocerebellar Ataxia (SCA), including Spinocerebellar Ataxia Type 3 (SCA3), a progressive and currently untreatable neurodegenerativ...

Cure Rare Disease Awarded $5.69 Million CIRM Grant to Advance Gene Therapy for Spinocerebellar Ataxia Type 3

WOODBRIDGE, Conn.--(BUSINESS WIRE)--Cure Rare Disease (CRD) announced it has been awarded a $5.69 million grant from the California Institute for Regenerative Medicine (CIRM) to advance the development of an antisense oligonucleotide therapy for spinocerebellar ataxia type 3 (SCA3), a neurodegenerative disorder with no current treatment. Cure Rare Disease launched its SCA3 program in 2021 to develop an antisense oligonucleotide (ASO) therapy, with initial funding support provided by Gregory Kla...
Back to Newsroom